Zydus Lifesciences (ZYDUSLIFE) — Financial Results

Zydus Lifesciences reported Q2 FY26 consolidated revenues of ₹61.2 billion, up 17% YoY, with net profit of ₹12.6 billion (up 38% YoY). EBITDA reached ₹20.2 billion with margins expanding 500 bps to 32.9%. US formulations grew 14% to ₹27.4 billion, while India branded formulations outpaced market at 9% growth. Key catalysts include Saroglitazar Phase III PBC trial success with planned launch within 14-15 months, Comfort Click acquisition for vitamins/minerals expansion, and Amplitude Surgical acquisition for orthopedic growth.

📄 View Original Announcement (PDF)

📊 Stock Analysis — ZYDUSLIFE ✨ Ask AI About This

About Zydus Lifesciences Limited (ZYDUSLIFE)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,01,800.69 Cr P/E: 22.5

View full ZYDUSLIFE stock details →

📡 Get AI alerts when ZYDUSLIFE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ZYDUSLIFE — Free

💡 Ask AI about this filing

"How does this financial results affect Zydus Lifesciences Limited's outlook?" "What did Zydus Lifesciences Limited announce on 13 November 2025?" "Is this positive or negative for ZYDUSLIFE?"

Ask AI Free →

📊 More ZYDUSLIFE filings

See all ZYDUSLIFE filings →

🔥 Also filed on 13 November 2025

EICHERMOT Eicher Motors Limited Corporate Action EICHERMOT Eicher Motors Limited Financial Results TORNTPHARM Torrent Pharmaceuticals Limited Financial Results BAJFINANCE Bajaj Finance Limited Financial Results DRREDDY Dr. Reddy's Laboratories Limited Corporate Action HEROMOTOCO Hero MotoCorp Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ZYDUSLIFE files new disclosures

Track ZYDUSLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.